{
  "id": "primary-prevention-2024",
  "title": "AHA/ASA Primary Prevention of Stroke 2024",
  "shortTitle": "Primary Prevention 2024",
  "doi": "10.1161/STR.0000000000000475",
  "publisherUrl": "https://www.ahajournals.org/doi/10.1161/STR.0000000000000475",
  "pdfUrl": "https://www.ahajournals.org/doi/pdf/10.1161/STR.0000000000000475",
  "recommendations": [
    {
      "section": "Patient Assessment",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "B-NR",
      "text": "1. In individuals 40\u201379 years of age, estimation of risk for atherosclerotic CVD (ie, nonfatal MI, nonfatal stroke, and fatal CVD) every 1 to 5 years is beneficial to guide decisions on treatments and lifestyle recommendations that may reduce risk for stroke.58",
      "page": 9
    },
    {
      "section": "Diet Quality",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "B-R",
      "text": "1. In adults without prior CVD and who are at high or intermediate CVD risk, a Mediterranean diet is recommended to reduce the risk of incident stroke.86,87",
      "page": 12
    },
    {
      "section": "Diet Quality",
      "classOfRec": "IIa",
      "classNote": null,
      "levelOfEvidence": "B-R",
      "text": "2. In adults who are \u226560 years of age and have uncontrolled BP (systolic BP [SBP] \u2265140 mm Hg if taking antihypertensive medication or \u2265160 mm Hg if not), compared with using 100% sodium chloride, salt substitution (75% sodium chloride and 25% potassium chloride) is reasonable to reduce the risk of incident stroke.88",
      "page": 12
    },
    {
      "section": "Diet Quality",
      "classOfRec": "IIb",
      "classNote": null,
      "levelOfEvidence": "B-NR",
      "text": "3. In adults, folic acid supplementation and B- complex (folic acid, B12, B6) vitamins supplementation for reducing the risk of stroke are not well established.89\u201391",
      "page": 12
    },
    {
      "section": "Diet Quality",
      "classOfRec": "III",
      "classNote": "No Benefit",
      "levelOfEvidence": "B-R",
      "text": "4. In adults without prior CVD, long-chain fatty acids are not effective for reducing the risk of stroke.89,91\u201396",
      "page": 12
    },
    {
      "section": "Diet Quality",
      "classOfRec": "III",
      "classNote": "No Benefit",
      "levelOfEvidence": "B-R",
      "text": "5. In adults, vitamin C, vitamin E, selenium, antioxidants, calcium, calcium with vitamin D, and multivitamin supplementation are not effective for reducing the risk of stroke.89\u201391,97\u201399",
      "page": 12
    },
    {
      "section": "Physical Activity",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "C-EO",
      "text": "1. In adults, screening for physical activity is recommended as part of a comprehensive effort to estimate stroke risk.104\u2013107 Other interventions",
      "page": 14
    },
    {
      "section": "Physical Activity",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "C-LD",
      "text": "2. In adults, counseling patients to engage in at least 150 minutes of moderate-intensity physical activity, 75 minutes of vigorous-intensity physical activity, or an equivalent combination per week is recommended to reduce the risk of stroke.108\u2013111",
      "page": 14
    },
    {
      "section": "Physical Activity",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "C-LD",
      "text": "3. In adults, counseling to avoid excessive time spent in sedentary behavior (characterized by lowenergy expenditure while sitting, reclining, or lying while awake) is recommended to reduce the risk of stroke.112\u2013115",
      "page": 14
    },
    {
      "section": "Weight and Obesity",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "B-NR",
      "text": "1. In adults >18 years of age, screening for overweight and obesity is recommended to inform the risk of stroke.158\u2013162 Other intervention",
      "page": 16
    },
    {
      "section": "Weight and Obesity",
      "classOfRec": "IIb",
      "classNote": null,
      "levelOfEvidence": "C-LD",
      "text": "2. In patients with class II obesity (35\u201339.9 kg/m2) or greater, bariatric surgical procedures to promote weight loss may be considered to reduce the risk of stroke.163\u2013167",
      "page": 16
    },
    {
      "section": "Sleep",
      "classOfRec": "IIb",
      "classNote": null,
      "levelOfEvidence": "B-R",
      "text": "1. The effectiveness of screening adults for OSA to prevent stroke is unclear.191 Other intervention",
      "page": 17
    },
    {
      "section": "Sleep",
      "classOfRec": "IIb",
      "classNote": null,
      "levelOfEvidence": "C-LD",
      "text": "2. In patients with OSA, continuous positive airway pressure (CPAP) might be reasonable to reduce the risk of stroke.192\u2013194",
      "page": 17
    },
    {
      "section": "Blood Sugar",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "C-LD",
      "text": "1. In asymptomatic adults \u226518 years of age who have overweight, obesity, or atherosclerotic CVD, screening for prediabetes and diabetes is recommended to inform stroke risk.202\u2013204 Other interventions",
      "page": 18
    },
    {
      "section": "Blood Sugar",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "A",
      "text": "2. In patients with diabetes and high cardiovascular risk or established CVD and hemoglobin A1c \u22657%, treatment with a GLP-1 receptor agonist is effective to reduce the risk of stroke.180,205\u2013208 Downloaded from http://ahajournals.org by on February 1, 2026 CLINICAL STATEMENTS AND GUIDELINES e362 December 2024 Stroke. 2024;55:e344\u2013e424. DOI: 10.1161/STR.0000000000000475 Bushnell et al 2024 Guideline for the Primary Prevention of Stroke",
      "page": 18
    },
    {
      "section": "Blood Sugar",
      "classOfRec": "III",
      "classNote": "No Benefit",
      "levelOfEvidence": "B-R",
      "text": "3. In patients with type 1 diabetes or diabetes, intensive glycemic control (targeting a hemoglobin A1c \u22646.5%) is not beneficial for stroke prevention.209\u2013215",
      "page": 19
    },
    {
      "section": "Blood Pressure",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "C-LD",
      "text": "1. In adults \u226518 years of age, screening for hypertension is recommended to identify individuals at increased risk for stroke and eligible for antihypertensive treatment.221 Other interventions",
      "page": 20
    },
    {
      "section": "Blood Pressure",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "A",
      "text": "2. In adults with stage 2 hypertension or stage 1 hypertension with a higher risk for atherosclerotic CVD, lifestyle improvement and antihypertensive drug treatment to a SBP/diastolic BP (DBP) <130/80 mm Hg are recommended to prevent stroke.222\u2013229",
      "page": 20
    },
    {
      "section": "Blood Pressure",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "A",
      "text": "3. In adults with hypertension, thiazide and thiazidelike diuretics, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers are recommended as initial antihypertensive drug therapies to prevent stroke.68,230\u2013232",
      "page": 20
    },
    {
      "section": "Blood Pressure",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "A",
      "text": "4. In most adults with hypertension, antihypertensive drug treatment incorporating \u22652 antihypertensive medications is indicated to achieve the BP control necessary to prevent stroke.224,229,234\u2013237",
      "page": 20
    },
    {
      "section": "Lipids",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "A",
      "text": "1. In adults who qualify for treatment with lipidlowering therapy according to the 2019 ACC/ AHA guideline on the primary prevention of CVD (eg, 20\u201375 years of age with LDL cholesterol [LDL-C] level >190 mg/dL [>4.9 mmol/L], 10-year ASCVD risk \u226520%, or 10-year ASCVD risk \u22657 .5%\u2013<20% plus \u22651 risk enhancers), treatment with a statin is recommended to reduce the risk of a first stroke.243,244",
      "page": 22
    },
    {
      "section": "Lipids",
      "classOfRec": "IIb",
      "classNote": null,
      "levelOfEvidence": "A",
      "text": "2. In adults without CVD who qualify for treatment with lipid-lowering therapy, according to the 2019 ACC/AHA guideline on the primary prevention of CVD (eg, 20\u201375 years of age with LDL-C level >190 mg/dL [>4.9 mmol/L], 10-year ASCVD risk \u226520%, or 10-year ASCVD risk \u22657 .5%\u2013<20% plus \u22651 risk enhancers), who cannot reach goals or cannot tolerate other therapies such as statins, the benefit of treatment with alirocumab or evolocumab compared with other active lipid-lowering therapy for the reduction of the risk of a first stroke is uncertain.245",
      "page": 22
    },
    {
      "section": "Lipids",
      "classOfRec": "IIb",
      "classNote": null,
      "levelOfEvidence": "B-R",
      "text": "3. In adults who do not tolerate statin therapy and who have LDL-C >100 mg/dL and elevated cardiovascular risk, treatment with bempedoic acid to reduce the risk of a first stroke is not well established.246",
      "page": 22
    },
    {
      "section": "Lipids",
      "classOfRec": "III",
      "classNote": "No Benefit",
      "levelOfEvidence": "A",
      "text": "4. In adults with moderate or low intake of long-chain omega-3 fatty acid, supplementation is not recommended to reduce the risk of a first stroke.92",
      "page": 22
    },
    {
      "section": "Tobacco Use",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "B-NR",
      "text": "1. In all patients, screening for cigarette smoking, use of other forms of tobacco, use of electronic nicotine delivery systems such as electronic cigarettes (e-cigarettes) and vapes, and environmental tobacco smoke exposure (secondhand smoke exposure) is effective to inform stroke risk and target cessation interventions.254\u2013270 Prevention intervention",
      "page": 24
    },
    {
      "section": "Tobacco Use",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "B-NR",
      "text": "2. For patients who are nonusers of tobacco products, continued complete abstention from cigarette smoking, in addition to other tobacco products and electronic nicotine delivery systems, and avoidance of exposure to environmental tobacco smoke (secondhand smoke exposure) are recommended to avoid the associated increased risk of stroke.254,255,257\u2013263,265\u2013270 Cessation intervention",
      "page": 24
    },
    {
      "section": "Tobacco Use",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "A",
      "text": "3. For patients who are active cigarette smokers, smoking cessation pharmacotherapy delivered along with behavioral counseling is recommended, in preference to behavioral counseling alone, to facilitate smoking cessation.271\u2013277",
      "page": 24
    },
    {
      "section": "Tobacco Use",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "C-LD",
      "text": "4. For patients who are active cigarette smokers and users of other tobacco products (eg, electronic nicotine delivery systems), assistance with cessation is recommended to reduce the risk of stroke.260,271,278\u2013286",
      "page": 24
    },
    {
      "section": "Tobacco Use",
      "classOfRec": "IIa",
      "classNote": null,
      "levelOfEvidence": "B-R",
      "text": "5. For patients who are active cigarette smokers encountered in the hospital setting, providing smoking cessation pharmacotherapy along with behavioral counseling as the default treatment (\u201copt-out\u201d), in preference to providing such treatment only for patients expressing a willingness to quit smoking (\u201copt-in\u201d), can be beneficial to facilitate short-term smoking cessation and to increase engagement in smoking cessation treatment.287 ,288",
      "page": 24
    },
    {
      "section": "Tobacco Use",
      "classOfRec": "IIb",
      "classNote": null,
      "levelOfEvidence": "B-R",
      "text": "6. For patients who are active cigarette smokers, the long-term health benefits of using e-cigarettes in place of nicotine replacement therapy to facilitate cigarette smoking cessation are not well established.289\u2013291",
      "page": 24
    },
    {
      "section": "Asymptomatic Carotid Artery Stenosis",
      "classOfRec": "III",
      "classNote": "No Benefit",
      "levelOfEvidence": "B-NR",
      "text": "1. In the asymptomatic population, routine screening for carotid artery stenosis is not recommended to reduce the risk of stroke.306,307 Other interventions",
      "page": 26
    },
    {
      "section": "Asymptomatic Carotid Artery Stenosis",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "C-EO",
      "text": "2. In patients with asymptomatic carotid artery stenosis (ACS) >70%, shared decision-making between the patient and the health care team to decide between the 2 courses of treatment (carotid revascularization or medical management) is recommended to determine the best method of reducing stroke risk.",
      "page": 26
    },
    {
      "section": "Asymptomatic Carotid Artery Stenosis",
      "classOfRec": "IIa",
      "classNote": null,
      "levelOfEvidence": "B-NR",
      "text": "3. In patients with asymptomatic atherosclerotic carotid artery stenosis, medical treatment with statin can be beneficial to reduce the risk of stroke.308\u2013311",
      "page": 26
    },
    {
      "section": "Asymptomatic Carotid Artery Stenosis",
      "classOfRec": "IIb",
      "classNote": null,
      "levelOfEvidence": "B-R",
      "text": "4. In patients with asymptomatic atherosclerotic carotid artery stenosis >70% and low perioperative risk, the use of carotid revascularization, in addition to intensive medical therapy, may be reasonable to reduce the risk of stroke.309,312\u2013314",
      "page": 26
    },
    {
      "section": "Asymptomatic Carotid Artery Stenosis",
      "classOfRec": "IIb",
      "classNote": null,
      "levelOfEvidence": "B-NR",
      "text": "5. In patients with ACS >50%, annual carotid duplex ultrasound every 6 to 12 months might be reasonable to assess progression of disease and subsequent increased risk of stroke.308,315\u2013318",
      "page": 26
    },
    {
      "section": "Asymptomatic Carotid Artery Stenosis",
      "classOfRec": "IIb",
      "classNote": null,
      "levelOfEvidence": "B-NR",
      "text": "6. In patients with asymptomatic atherosclerotic carotid artery stenosis and high perioperative risk, the effectiveness of carotid revascularization to reduce risk of stroke is not established.314,319,320",
      "page": 26
    },
    {
      "section": "Asymptomatic Cerebral SVD, Including",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "C-LD",
      "text": "1. In adults with asymptomatic cerebral SVD (CSVD), including silent infarcts, assessment and management of risk factors (eg, hypertension, dyslipidemia, tobacco use, and diabetes) are recommended to reduce stroke risk.336\u2013341",
      "page": 29
    },
    {
      "section": "Asymptomatic Cerebral SVD, Including",
      "classOfRec": "IIb",
      "classNote": null,
      "levelOfEvidence": "B-NR",
      "text": "2. In adults with silent cerebral infarcts (SCIs) who do not have an indication for statin therapy according to the 2019 ACC/AHA guideline (eg, 20\u201375 years of age with LDL-C level >190 mg/dL [>4.9 mmol/L], 10-year ASCVD risk \u226520%, or 10-year ASCVD risk \u22657 .5%\u2013<20% plus \u22651 more risk enhancers), use of low-dose statin therapy might be considered to reduce the risk of ischemic stroke.342\u2013345",
      "page": 29
    },
    {
      "section": "Asymptomatic Cerebral SVD, Including",
      "classOfRec": "IIb",
      "classNote": null,
      "levelOfEvidence": "C-LD",
      "text": "3. In adults with SCI, the benefit of antiplatelet therapy to reduce the risk of ischemic stroke is uncertain.346,347",
      "page": 29
    },
    {
      "section": "Migraine",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "C-LD",
      "text": "1. In adults 18 to 64 years of age with migraine with or without aura, evaluation and modification of vascular risk factors are recommended to address the elevated risk of stroke in this patient population.362\u2013369",
      "page": 30
    },
    {
      "section": "Migraine",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "C-LD",
      "text": "2. In adults with migraine with aura who desire contraception, progestin-only or nonhormonal forms are recommended to avoid the increased risk of ischemic stroke associated with combined hormonal contraception.370\u2013372",
      "page": 30
    },
    {
      "section": "Sickle Cell Disease",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "B-R",
      "text": "1. In children 2 to 16 years of age with SCD (Hb SS or Hb S-beta0-thalassemia), transcranial Doppler (TCD) screening at a frequency based on the highest mean flow velocity in the terminal portion of the internal carotid or the proximal portion of the middle cerebral artery is recommended.381\u2013384 Other interventions",
      "page": 31
    },
    {
      "section": "Sickle Cell Disease",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "B-R",
      "text": "2. In children 2 to 16 years of age with SCD at elevated risk per TCD measurements, regularly scheduled transfusion therapy (target reduction of hemoglobin S <30%) is effective for reducing stroke risk.382,383",
      "page": 31
    },
    {
      "section": "Sickle Cell Disease",
      "classOfRec": "IIa",
      "classNote": null,
      "levelOfEvidence": "B-R",
      "text": "3. In children 2 to 16 years of age and young adults with Hb SS or Hb S-beta0-thalassemia, an MRI of the brain without sedation should be performed as soon as possible to evaluate for SCI and to determine the need for chronic red cell transfusions (CRCTs) for stroke prevention.385,386",
      "page": 31
    },
    {
      "section": "Sickle Cell Disease",
      "classOfRec": "IIa",
      "classNote": null,
      "levelOfEvidence": "B-R",
      "text": "4. In children 2 to 16 years of age with SCD whose TCD velocities revert to normal, continued transfusion therapy can be beneficial to reduce the risk of stroke.384",
      "page": 31
    },
    {
      "section": "Sickle Cell Disease",
      "classOfRec": "IIa",
      "classNote": null,
      "levelOfEvidence": "B-NR",
      "text": "5. In children 2 to 16 years of age with SCD and normalized mean flow velocities and no intracranial stenosis, transition from transfusion to hydroxyurea therapy can be considered to prevent stroke.387",
      "page": 31
    },
    {
      "section": "Sickle Cell Disease",
      "classOfRec": "IIb",
      "classNote": null,
      "levelOfEvidence": "B-NR",
      "text": "6. In children 2 to 16 years of age with SCD at high risk for stroke (TCD mean flow velocities \u2265200 cm/s) but without intracranial stenosis who are unable to continue or cannot be treated with periodic red cell transfusion, hydroxyurea or bone marrow transplantation may be reasonable to prevent stroke.387\u2013390",
      "page": 31
    },
    {
      "section": "Genetic Stroke Syndromes",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "C-LD",
      "text": "1. In patients with CADASIL, counseling on smoking cessation and treatment of hypertension and other vascular risk factors are beneficial to reduce the risk of incident stroke.407\u2013412",
      "page": 34
    },
    {
      "section": "Genetic Stroke Syndromes",
      "classOfRec": "IIa",
      "classNote": null,
      "levelOfEvidence": "B-NR",
      "text": "2. In adults with hereditary hemorrhagic telangiectasia (HHT), screening for pulmonary arteriovenous malformations (PAVMs) is reasonable to identify the need for multidisciplinary evaluation to manage stroke risk.413\u2013421",
      "page": 34
    },
    {
      "section": "Genetic Stroke Syndromes",
      "classOfRec": "IIb",
      "classNote": null,
      "levelOfEvidence": "C-LD",
      "text": "3. In patients with Fabry disease, the effectiveness of enzyme replacement therapy (ERT) to reduce the risk of stroke is not well established.422\u2013427",
      "page": 34
    },
    {
      "section": "Inflammation in Atherosclerosis",
      "classOfRec": "IIb",
      "classNote": null,
      "levelOfEvidence": "B-R",
      "text": "1. In adults with a recent MI, the addition of lowdose colchicine to intensive statin therapy might be reasonable to decrease the risk of ischemic stroke.457 ,458",
      "page": 36
    },
    {
      "section": "Inflammation in Atherosclerosis",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "B-NR",
      "text": "1. In patients without a history of stroke and no clinical indication for anticoagulation, with a high-risk aPL profile (ie, triple-positive antiphospholipid testing [lupus anticoagulant, anticardiolipin antibody, anti\u2013\u03b22 glycoprotein 1] or double-positive [any combination] or isolated lupus anticoagulant or isolated persistently positive anticardiolipin antibody at medium to high titers), prophylactic treatment with aspirin (75\u2013100 mg daily) is recommended to reduce the risk of stroke.462,463",
      "page": 37
    },
    {
      "section": "Inflammation in Atherosclerosis",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "B-NR",
      "text": "2. In patients with systemic lupus erythematosus (SLE) and no history of thrombosis or pregnancy complications and with a high-risk antiphospholipid profile (ie, lupus anticoagulant, anticardiolipin antibody, anti\u2013\u03b22-glycoprotein 1, or double-positive [any combination] or isolated lupus anticoagulant or isolated persistently positive anticardiolipin antibody at medium to high titers), prophylactic treatment with aspirin (75\u2013100 mg daily) is recommended to reduce the risk of stroke.462,463",
      "page": 37
    },
    {
      "section": "Inflammation in Atherosclerosis",
      "classOfRec": "IIa",
      "classNote": null,
      "levelOfEvidence": "B-R",
      "text": "3. In patients with antiphospholipid syndrome (APS) with prior unprovoked venous thrombosis, it is reasonable to choose vitamin K antagonist (VKA) therapy with a target international normalized ratio of 2 to 3 in preference to aspirin or direct oral anticoagulants for prevention of recurrent thrombotic events, including stroke.457 ,458.464,465",
      "page": 37
    },
    {
      "section": "Inflammation in Atherosclerosis",
      "classOfRec": "IIb",
      "classNote": null,
      "levelOfEvidence": "B-R",
      "text": "4. In patients with rheumatoid arthritis, statin treatment may be reasonable to reduce major adverse cardiovascular events, including stroke.466,467",
      "page": 37
    },
    {
      "section": "Inflammation in Atherosclerosis",
      "classOfRec": "IIb",
      "classNote": null,
      "levelOfEvidence": "B-NR",
      "text": "5. In nonpregnant adults with a history of obstetric APS only, prophylactic treatment with aspirin (75\u2013100 mg daily) after adequate risk/benefit evaluation (ie, aPL profile, coexistent traditional cardiovascular risk factors, intolerance, or contraindication to aspirin) may be considered to reduce the risk of stroke.462,468",
      "page": 37
    },
    {
      "section": "Inflammation in Atherosclerosis",
      "classOfRec": "IIb",
      "classNote": null,
      "levelOfEvidence": "C-LD",
      "text": "6. In patients with SLE and no history of thrombosis or pregnancy complications and with a low-risk antiphospholipid profile (ie, isolated anticardiolipin antibody or anti\u2013\u03b22-glycoprotein 1 antibodies at low to medium titers, particularly if transiently positive), prophylactic treatment with aspirin (75\u2013100 mg daily) may be considered to reduce the risk of stroke.462,463,469,470",
      "page": 37
    },
    {
      "section": "Infection",
      "classOfRec": "IIa",
      "classNote": null,
      "levelOfEvidence": "B-NR",
      "text": "1. In patients with periodontal disease (PD), good oral hygiene and regular dental care can be beneficial to lower stroke risk.486\u2013488",
      "page": 39
    },
    {
      "section": "Infection",
      "classOfRec": "III",
      "classNote": "No Benefit",
      "levelOfEvidence": "B-R",
      "text": "2. In patients hospitalized with COVID-19, treatment with full-dose anticoagulation (eg, enoxaparin, apixaban) is not recommended to prevent stroke.489,490",
      "page": 39
    },
    {
      "section": "Substance Use and Substance Disorders",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "B-NR",
      "text": "1. In all adults, screening for substance misuse and substance use disorders (eg, alcohol, cannabis, cocaine, opioids, amphetamines) is recommended to inform stroke risk.506\u2013520 Other interventions",
      "page": 40
    },
    {
      "section": "Substance Use and Substance Disorders",
      "classOfRec": "IIa",
      "classNote": null,
      "levelOfEvidence": "C-LD",
      "text": "2. In patients who use recreational drugs (eg, cannabis, synthetic cannabinoids, cocaine, heroin, methamphetamine), misuse alcohol or prescription medications (eg, stimulants and opioids), or have a substance use disorder, counseling to stop or appropriate substance use disorder treatments (eg, pharmacological, behavioral, or multimodal) as appropriate are reasonable to reduce stroke risk.521\u2013531 Downloaded from http://ahajournals.org by on February 1, 2026 CLINICAL STATEMENTS AND GUIDELINES e384 December 2024 Stroke. 2024;55:e344\u2013e424. DOI: 10.1161/STR.0000000000000475 Bushnell et al 2024 Guideline for the Primary Prevention of Stroke",
      "page": 40
    },
    {
      "section": "Prevention of Pregnancy-Associated Stroke",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "B-NR",
      "text": "1. In pregnant or early postpartum (within 6 weeks of delivery), patients with severe hypertension (2 measurements of SBP \u2265160 mm Hg or DBP \u2265110 mm Hg, 15 minutes apart), BP-lowering treatment to a target <160/110 mm Hg as soon as possible is recommended to reduce the risk of fatal maternal ICH.551\u2013558",
      "page": 42
    },
    {
      "section": "Prevention of Pregnancy-Associated Stroke",
      "classOfRec": "IIa",
      "classNote": null,
      "levelOfEvidence": "C-LD",
      "text": "2. In patients with HDP, including chronic hypertension in pregnancy, treatment with antihypertensive medication to a goal BP of <140/90 mm Hg is reasonable to reduce the risk of pregnancyassociated stroke.559\u2013566",
      "page": 42
    },
    {
      "section": "Pregnancy and Long-Term Stroke Risk",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "C-EO",
      "text": "1. In adults, screening for a history of certain adverse pregnancy outcomes (APOs), including HDP, preterm birth, gestational diabetes, and placental disorders, followed by subsequent evaluation and management of vascular risk factors, is recommended to reduce the risk of stroke. Other intervention",
      "page": 44
    },
    {
      "section": "Pregnancy and Long-Term Stroke Risk",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "C-LD",
      "text": "2. In patients with a history of HDP or other APOs, early evaluation and management of chronic hypertension are recommended to reduce the risk of stroke.609\u2013613",
      "page": 44
    },
    {
      "section": "Endometriosis",
      "classOfRec": "IIa",
      "classNote": null,
      "levelOfEvidence": "B-NR",
      "text": "1. In adults, screening for a history of endometriosis is reasonable to inform the risk of stroke.649\u2013653 Other intervention",
      "page": 47
    },
    {
      "section": "Endometriosis",
      "classOfRec": "IIa",
      "classNote": null,
      "levelOfEvidence": "C-LD",
      "text": "2. In individuals with endometriosis, vascular risk factor evaluation and modification of vascular risk factors are reasonable to reduce the risk of stroke.649\u2013653",
      "page": 47
    },
    {
      "section": "Hormonal Contraception",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "B-NR",
      "text": "1. In individuals considering CHC, lower doses of ethinyl estradiol are recommended to minimize potential increased stroke risk.658\u2013663",
      "page": 48
    },
    {
      "section": "Hormonal Contraception",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "C-EO",
      "text": "2. In individuals with specific stroke risk factors (ie, age >35 years, tobacco use, hypertension, or migraine with aura) who are considering contraception, shared decision-making is recommended to determine the best contraceptive choice to balance the risk of stroke from contraception and the risk of stroke with pregnancy.",
      "page": 48
    },
    {
      "section": "Hormonal Contraception",
      "classOfRec": "IIa",
      "classNote": null,
      "levelOfEvidence": "C-LD",
      "text": "3. In individuals with specific stroke risk factors (ie, age >35 years, tobacco use, hypertension, or migraine with aura) who are considering contraception, progestin-only contraception or nonhormonal contraception is reasonable to prevent the increased stroke risk associated with estrogencontaining contraception.370,661\u2013670",
      "page": 48
    },
    {
      "section": "Menopause",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "B-NR",
      "text": "1. Screening for a history of premature ovarian failure (before 40 years of age) and early menopause (before 45 years of age) can be beneficial to inform the risk of stroke.674\u2013678 Other interventions",
      "page": 49
    },
    {
      "section": "Menopause",
      "classOfRec": "I",
      "classNote": null,
      "levelOfEvidence": "C-LD",
      "text": "2. In patients with premature ovarian failure (menopause before 40 years of age) or early menopause (before 45 years of age), evaluation and modification of vascular risk factors are recommended to reduce the elevated stroke risk in this population.674,675,677\u2013679",
      "page": 49
    },
    {
      "section": "Menopause",
      "classOfRec": "III",
      "classNote": "Harm",
      "levelOfEvidence": "A",
      "text": "3. In women \u226560 years of age, more than 10 years after natural menopause, or at elevated risk for CVD or stroke, oral estrogen-containing menopausal HT is associated with an excess risk of stroke and must be weighed against clinical benefits.658,680\u2013683",
      "page": 49
    },
    {
      "section": "Transgender Health",
      "classOfRec": "IIa",
      "classNote": null,
      "levelOfEvidence": "C-LD",
      "text": "1. In transgender women and gender-diverse individuals taking estrogens for gender affirmation, evaluation and modification of risk factors can be beneficial to reduce the risk of stroke.700\u2013703",
      "page": 51
    },
    {
      "section": "Testosterone Use",
      "classOfRec": "IIa",
      "classNote": null,
      "levelOfEvidence": "B-R",
      "text": "1. In men 45 to 80 years of age with confirmed hypogonadism who are considering testosterone therapy, initiation or continuation of testosterone replacement therapy is reasonable and does not increase the risk of stroke.704\u2013706",
      "page": 52
    },
    {
      "section": "Cardiomyopathy",
      "classOfRec": "III",
      "classNote": "No Benefit",
      "levelOfEvidence": "B-R",
      "text": "1. In patients with left ventricular systolic dysfunction (ejection fraction \u226435%\u201340%) and no evidence of AF or left ventricular thrombus, anticoagulation is not indicated to prevent stroke and is associated with a higher bleeding risk.706,708\u2013711",
      "page": 53
    },
    {
      "section": "Antiplatelet Use for Primary Prevention",
      "classOfRec": "IIb",
      "classNote": null,
      "levelOfEvidence": "A",
      "text": "1. In patients with diabetes or other common vascular risk factors and no prior stroke, the use of aspirin to prevent a first stroke is not well established.727\u2013731",
      "page": 54
    },
    {
      "section": "Antiplatelet Use for Primary Prevention",
      "classOfRec": "IIb",
      "classNote": null,
      "levelOfEvidence": "B-R",
      "text": "2. In patients with established, stable coronary artery disease and a low bleeding risk, the addition of ticagrelor to aspirin beyond 12 months for a period up to 3 years may be beneficial to reduce the rate of ischemic stroke.732",
      "page": 54
    },
    {
      "section": "Antiplatelet Use for Primary Prevention",
      "classOfRec": "III",
      "classNote": "No Benefit",
      "levelOfEvidence": "A",
      "text": "3. In individuals \u226570 years of age with at least 1 additional cardiovascular risk factor, the use of aspirin is not beneficial to prevent a first stroke.360,733",
      "page": 54
    },
    {
      "section": "Antiplatelet Use for Primary Prevention",
      "classOfRec": "III",
      "classNote": "No Benefit",
      "levelOfEvidence": "B-NR",
      "text": "4. In patients with chronic kidney disease, the use of aspirin is not effective to prevent a first stroke.734",
      "page": 54
    }
  ]
}